The European Medicines Agency (EMA) has granted limited approval to Eli Lilly’s (LLY) new Alzheimer’s drug Kisunla, reversing ...

While more research is needed, including human trials, the results are promising. The drug SW033291 could lead to a new type ...

What if your doctor could, when you turn 65, order a test that predicts whether you are going to develop Alzheimer’s dementia in your 70s or 80s? And what if – in case the test comes back ...

Without the receptor, ADGRG1, the microglia barely nibbled on the toxic protein. Using a mouse model of Alzheimer’s disease, the researchers observed how the loss of ADGRG1 led to the rapid buildup of ...

Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

A tiny flower-shaped particle could help to pave the way for a new treatment approach to Alzheimer's and Parkinson's that targets the root causes.

In terms of quality of life, someone 75 years old, retired with significant memory problems, can still have friends and, “a ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.

The harmful clumps of tau protein that build up in brains affected by Alzheimer's were reduced significantly, and the mice ...